User:Mr. Ibrahem/Sodium zirconium cyclosilicate
 Crystal structure of ZS-9. Blue spheres = oxygen atoms, red spheres = zirconium atoms, green spheres = silicon atoms. | |
| Clinical data | |
|---|---|
| Trade names | Lokelma |
| AHFS/Drugs.com | Monograph |
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Not absorbed |
| Excretion | Stool |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | (2Na·H2O·3H4SiO4·H4ZrO6)n |
Sodium zirconium cyclosilicate (ZS-9), sold under the brand name Lokelma, is a medication used to treat high blood potassium.[2] Onset of effects occurs in one to six hours.[2] It is taken by mouth.[2]
Common side effects include swelling and low blood potassium.[2] Use is likely safe in pregnancy and breastfeeding.[2] It works by binding potassium ions in the gastrointestinal tract which is then lost in the stool.[2][3]
Sodium zirconium cyclosilicate was approved for medical use in the European Union and in the United States in 2018.[2][4][5] It was developed by AstraZeneca.[2] In the United States it costs about $US24 per dose.[6] In the United Kingdom as of 2019 it costs the NHS about £7.12 per dose.[7]
References[edit]
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 5 September 2020.
- ^ a b c d e f g h "Sodium Zirconium Cyclosilicate Monograph for Professionals". Drugs.com. Retrieved 11 October 2019.
- ^ Hoy SM (October 2018). "Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia". Drugs. 78 (15): 1605–1613. doi:10.1007/s40265-018-0991-6. PMC 6433811. PMID 30306338.
- ^ "Lokelma EPAR". European Medicines Agency (EMA). Retrieved 11 October 2019.
- ^ "Drug Approval Package: Lokelma (sodium zirconium cyclosilicate)". U.S. Food and Drug Administration (FDA). 8 June 2018. Retrieved 7 May 2020.
- ^ "Lokelma Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 October 2019.
- ^ "Sodium zirconium cyclosilicate". NICE. Retrieved 11 October 2019.